Risk factor modification remains as the principal aspect of care for stroke prevention. Understanding of risk factors has advanced and several options are now available to treat modifiable risk factors. However, effective treatment remains a challenging task in clinical practice. Prevention begins with awareness of risk factors by patients and clinicians. Risk factor assessment along with overall stroke risk estimation should be part of evaluation of patients with stroke, and used with careful clinical judgment. In this review, we discuss the impact of modifiable traditional vascular risk factors on ischemic stroke, interventions for stroke prevention, and evidence for early treatment of risk factors where available, as well as areas of research progress. Emphasis should be put on the education of patients, the community, and medical personnel. Future research in the field of genetic determinants of vascular risk factors and stroke will increase our understanding of the underlying mechanisms of cerebrovascular disease and likely result in development of new therapies and individualized programs for stroke prevention.
Accord-Study-Group. (2008 ) Effects of Intensive Glucose Lowering in Type 2 Diabetes . N Engl J Med358: 2545-2559.
2.
Albucher, J.F., Ferrieres, J., Ruidavets, J.B., Guiraud-Chaumeil, B., Perret, B.P., Chollet, F. (2000) Serum lipids in young patients with ischaemic stroke: a case-control study. J Neurol Neurosurg Psychiatry69: 29-33.
3.
Alvarez-Sabin, J., Huertas, R., Quintana, M., Rubiera, M., Delgado, P., Ribo, M. et al. (2007) Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke38: 1076-1078.
4.
Amarenco, P. (2005) Effect of statins in stroke prevention. Curr Opin Lipidol16: 614-618.
5.
Amarenco, P., Bogousslavsky, J., Callahan, A., 3rd, Goldstein, L.B., Hennerici, M., Rudolph, A.E. et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med355: 549-559.
6.
Arauz-Pacheco, C., Parrott, M.A. and Raskin, P. (2002) The treatment of hypertension in adult patients with diabetes. Diabetes Care25: 134-147.
7.
Athyros, V.G., Papageorgiou, A.A., Mercouris, B.R., Athyrou,V.V., Symeonidis, A.N., Basayannis, E.O. et al. (2002) Treatment with atorvastatin to the national cholesterol educational program goal vs. `usual' care in secondary coronary heart disease prevention. The greek atorvastatin and coronary-heart-disease evaluation (Greace) study. Curr Med Res Opin18: 220-228.
8.
Atrial-Fibrillation-Investigators. (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med154: 1449-1457.
9.
Blanco, M., Nombela, F., Castellanos, M., Rodriguez-Yanez, M., Garcia-Gil, M., Leira, R. et al. (2007) Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology69: 904-910.
10.
Bodenheimer, T. (2007) A 63-year-old man with multiple cardiovascular risk factors and poor adherence to treatment plans. Jama298: 2048-2055.
11.
Bruno, A., Levine, S.R., Frankel, M.R., Brott, T.G., Lin, Y.,Tilley, B.C. et al. (2002) Admission glucose level and clinical outcomes in the ninds Rt-Pa stroke trial. Neurology59: 669-674.
12.
Cdc. (2004) Cigarette smoking among adults - United States, 2002. Morbidity and Mortality Weekly Report. Vol. 53: 427-431.
13.
Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo Jr, J.L. et al. (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the Jnc 7 report. Jama289: 2560-2572.
14.
Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J. et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (Cards): multicentre randomised placebo-controlled trial. Lancet364: 685-696.
15.
Collins, R., Armitage, J., Parish, S., Sleight, P. and Peto, R. (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet363: 757-767.
16.
Colwell, J.A. (1997) Aspirin therapy in diabetes. Diabetes Care20: 1767-1771.
17.
Curb, J.D., Abbott, R.D., Rodriguez, B.L., Masaki, K.H., Chen, R., Popper, J.S. et al. (2004) High density lipoprotein cholesterol and the risk of stroke in elderly men: the honolulu heart program. Am J Epidemiol160: 150-157.
18.
Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., De Faire, U. et al. (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (Life): A randomised trial against atenolol. Lancet359: 995-1003.
19.
Deplanque, D., Leys, D., Parnetti, L., Schmidt, R., Ferro, J., De Reuck, J. et al. (2006) Secondary prevention of stroke in patients with atrial fibrillation: factors influencing the prescription of oral anticoagulation at discharge. Cerebrovasc Dis21: 372-379.
20.
Deplanque, D., Masse, I., Lefebvre, C., Libersa, C., Leys, D. and Bordet, R. (2006) Prior tia, lipid-lowering drug use, and physical activity decrease ischemic stroke severity. Neurology67: 1403-1410.
21.
Dobkin, B. (1995) The economic impact of stroke. Neurology45: S6-S9.
22.
Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K. et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet366: 1279-1289.
23.
Elkind, M.S., Flint, A.C., Sciacca, R.R. and Sacco, R.L. (2005) Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology65: 253-258.
24.
Endres, M. (2005) Statins and stroke. J Cereb Blood Flow Metab25: 1093-1110.
25.
Estacio, R.O., Jeffers, B.W., Hiatt, W.R., Biggerstaff, S.L., Gifford, N. and Schrier, R.W. (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med338: 645-652.
26.
European-Atrial-Fibrillation-Trial-Investigators. (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Eaft (European Atrial Fibrillation Trial) Study Group. Lancet342: 1255-1262.
27.
Fisher, W.D., Eriksson, B.I., Bauer, K.A., Borris, L., Dahl, O.E., Gent, M. et al. (2007) Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost97: 931-937.
28.
Flegal, K.M., Carroll, M.D., Ogden, C.L. and Johnson, C.L. (2002) Prevalence and trends in obesity among us adults, 1999-2000. Jama288: 1723-1727.
29.
Flegal, K.M., Graubard, B.I.,Williamson, D.F. and Gail, M.H. (2005) Excess deaths associated with underweight, overweight, and obesity. Jama293: 1861-1867.
30.
Genuth, S., Alberti, K.G., Bennett, P., Buse, J., Defronzo, R., Kahn, R. et al. (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care26: 3160-3167.
31.
Gerstein, H.C.,Yusuf, S., Bosch, J., Pogue, J., Sheridan, P., Dinccag, N. et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet368: 1096-1105.
32.
Go, A.S., Hylek, E.M., Chang, Y., Phillips, K.A., Henault, L.E., Capra, A.M. et al. (2003) Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? Jama290: 2685-2692.
33.
Goldstein, L.B., Adams, R., Alberts, M.J., Appel, L.J., Brass, L.M., Bushnell, C.D. et al. (2006) primary prevention of ischemic stroke: a guideline from the American heart association/ American stroke association stroke council: cosponsored by the atherosclerotic peripheral vascular disease interdisciplinary working group; cardiovascular nursing council; clinical cardiology council; nutrition, physical activity, and metabolism council; and the quality of care and outcomes research interdisciplinary working group: the American academy of neurology affirms the value of this guideline. Stroke37: 1583-1633.
34.
Gonzales, D., Rennard, S.I., Nides, M., Oncken, C., Azoulay, S., Billing, C.B. et al. (2006) Varenicline, an Alpha4beta2 Nicotinic Acetylcholine Receptor Partial Agonist, Vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial. Jama296: 47-55.
35.
Haffner, S.M. (1998) Management of dyslipidemia in adults with diabetes . Diabetes Care21: 160-178.
36.
Hajjar, I., Kotchen, J.M. and Kotchen, T.A. (2006) Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health27: 465-490.
37.
Hampton, T. (2006) Researchers draft guidelines for clinical use of pharmacogenomics. Jama296: 1453-1454.
38.
Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S. et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (Hot) randomised trial. Hot study group. Lancet351: 1755-1762.
39.
Hickenbottom, S.L., Fendrick, A.M., Kutcher, J.S., Kabeto, M.U., Katz, S.J., Langa, K.M. (2002) A national study of the quantity and cost of informal caregiving for the elderly with stroke. Neurology58: 1754-1759.
40.
Hope-Study-Investigators. (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the hope study and micro-hope substudy. Heart outcomes prevention evaluation study investigators. Lancet355: 253-259.
41.
Hylek, E.M., Skates, S.J., Sheehan, M.A. and Singer, D.E. (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation . N Engl J Med335: 540-546.
42.
Ikram, M.A., Vernooij, M.W., Hofman, A., Niessen,W.J.,Van Der Lugt, A. and Breteler, M.M. (2008) Kidney function is related to cerebral small vessel disease. Stroke39: 55-61.
43.
Jorenby, D.E., Leischow, S.J., Nides, M.A., Rennard, S.I., Johnston, J.A., Hughes, A.R. et al. (1999) A Controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med340: 685-691.
44.
Julius, S., Nesbitt, S.D., Egan, B.M., Weber, M.A., Michelson, E.L., Kaciroti, N. et al. (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med354: 1685-1697.
45.
Kaarisalo, M.M., Raiha, I., Arve, S. and Lehtonen, A. (2006) Impaired glucose tolerance as a risk factor for stroke in a cohort of non-institutionalised people aged 70 years. Age Ageing35: 592-596.
46.
Kannel, W.B. (2000) Risk Stratification in Hypertension: new insights from the framingham study. Am J Hypertens13: 3S-10S.
47.
Kernan, W.N., Inzucchi, S.E., Viscoli, C.M., Brass, L.M., Bravata, D.M. and Horwitz, R.I. (2002) Insulin resistance and risk for stroke. Neurology59: 809-815.
48.
Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A. et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med346: 393-403.
49.
Lancaster, T., Stead, L., Silagy, C. and Sowden, A. (2000) Effectiveness of interventions to help people stop smoking: findings from the cochrane library. Bmj321: 355-358.
50.
Levine, M.N., Raskob, G., Beyth, R.J., Kearon, C. and Schulman, S. (2004) Hemorrhagic complications of anticoagulant treatment: the seventh accp conference on antithrombotic and thrombolytic therapy. Chest126: 287S-310S.
51.
Lewington, S., Clarke, R., Qizilbash, N., Peto, R. and Collins, R. (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360: 1903-1913.
52.
Lin, H.J., Wolf, P.A., Kelly-Hayes, M., Beiser, A.S., Kase, C.S., Benjamin, E.J. et al. (1996) Stroke severity in atrial fibrillation. The framingham study. Stroke27: 1760-1764.
53.
Linder, M.W., Looney, S., Adams, J.E., 3rd, Johnson, N., Antonino-Green, D., Lacefield, N. et al. (2002) Warfarin dose adjustments based on cyp2c9 genetic polymorphisms. J Thromb Thrombolysis14: 227-232.
54.
Lindstrom, J., Ilanne-Parikka, P., Peltonen, M., Aunola, S., Eriksson, J.G., Hemio, K. et al. (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the finnish diabetes prevention study. Lancet368: 1673-1679.
55.
Lloyd-Jones, D.M., Wang, T.J., Leip, E.P., Larson, M.G., Levy, D., Vasan, R.S. et al. (2004) Lifetime risk for development of atrial fibrillation: the framingham heart study. Circulation110: 1042-1046.
56.
Man-Son-Hing, M. and Laupacis, A. (2003) Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med163: 1580-1586.
57.
Man-Son-Hing, M., Nichol, G., Lau, A. and Laupacis, A. (1999) Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med159: 677-685.
National-Diabetes-Statistics-Niddk. (2005) National diabetes statistics; total prevalence of diabetes in the United States, all ages, 2005. In: Niddk, N.I.O.H.U.S.D.O.H.A.H.S., ed: NIH
60.
Nissen, S.E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med356: 2457-2471.
61.
Olsson, S.B. (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (Sportif III): randomised controlled trial. Lancet362: 1691-1698.
62.
Ovbiagele, B. and Saver, J.L. (2006) Ensuring management of vascular risk factors after stroke. Rev Neurol Dis3: 93-100.
63.
Papademetriou, V., Farsang, C., Elmfeldt, D., Hofman, A., Lithell, H., Olofsson, B. et al. (2004) Stroke prevention with the angiotensin ii type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on cognition and prognosis in the elderly (Scope) . J Am Coll Cardiol44: 1175-1180.
64.
Parsons, M.W., Barber, P.A., Desmond, P.M., Baird, T.A., Darby, D.G., Byrnes, G. et al. (2002) Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol52: 20-28.
65.
Petersen, P., Boysen, G., Godtfredsen, J., Andersen, E.D. and Andersen, B. (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The copenhagen afasak Study. Lancet1: 175-179.
66.
Prochazka, A.V., Weaver, M.J., Keller, R.T., Fryer, G.E., Licari, P.A. and Lofaso, D. (1998) A randomized trial of nortriptyline for smoking cessation. Arch Intern Med158: 2035-2039.
67.
Progress-Collaborative-Group. (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack . Lancet358: 1033-1041.
68.
Pyorala, M., Miettinen, H., Halonen, P., Laakso, M. and Pyorala, K. (2000) Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the helsinki policemen study. Arterioscler ThrombVasc Biol20: 538-544.
69.
Rieder, M.J., Reiner, A.P., Gage, B.F., Nickerson, D.A., Eby, C.S., Mcleod, H.L. et al. (2005) Effect of vkorc1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med352: 2285-2293.
70.
Rodgers, A., Macmahon, S., Gamble, G., Slattery, J., Sandercock, P. and Warlow, C. (1996) Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom transient ischaemic attack collaborative group. Bmj313: 147.
71.
Rosamond, W., Faha, K., Furie, K., Go, A., Greenlund, K., Haase, N. et al. (2008) Heart disease and stroke statistics-2008 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation117: e25-e146.
72.
Ryden, L., Standl, E., Bartnik, M., Van Den Berghe, G., Betteridge, J., De Boer, M.J. et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive Summary. The task force on diabetes and cardiovascular diseases of the european society of cardiology (Esc) and of the European Association for the Study of Diabetes (Easd). Eur Heart J28: 88-136.
Sacco, R.L., Adams, R., Albers, G., Alberts, M.J., Benavente, O., Furie, K. et al. (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American heart association/American stroke association council on stroke: co-sponsored by the council on cardiovascular radiology and intervention: the American academy of neurology affirms the value of this guideline. Stroke37: 577-617.
75.
Sandercock, P., Bamford, J., Dennis, M., Burn, J., Slattery, J., Jones, L. et al. (1992) Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (oxfordshire community stroke project). Bmj305: 1460-1465.
76.
Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L., King, B.P. et al. (2005) The impact of Cyp2c9 and vkorc1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood106: 2329-2333.
77.
Sever, P.S., Dahlof, B., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M. et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm (Ascot-Lla): A multicentre randomised controlled trial. Lancet361: 1149-1158.
78.
Shahar, E., Chambless, L.E., Rosamond, W.D., Boland, L.L., Ballantyne, C.M., Mcgovern, P.G. et al. (2003) Plasma lipid profile and incident ischemic stroke: the atherosclerosis risk in communities (aric) study. Stroke34: 623-631.
79.
Shinton, R. and Beevers, G. (1989) Meta-analysis of relation between cigarette smoking and stroke. Bmj298: 789-794.
80.
Silagy, C., Mant, D., Fowler, G. and Lancaster, T. (2000) Nicotine replacement therapy for smoking cessation . Cochrane Database Syst Rev: CD000146.
81.
Spaf-Iii-Trial-Investigators. (1996) Adjusted-dose warfarin vs. low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation iii randomised clinical trial. Lancet348: 633-638.
82.
Suk, S.H., Sacco, R.L., Boden-Albala, B., Cheun, J.F., Pittman, J.G., Elkind, M.S. et al. (2003) Abdominal obesity and risk of ischemic stroke: the northern manhattan stroke study. Stroke34: 1586-1592.
83.
Tall, A.R. (1990) Plasma high density lipoproteins. metabolism and relationship to atherogenesis. J Clin Invest86: 379-384.
84.
The-Expert-Committee-on-the-Diagnosis-and-Classification-of-Diabetes-Mellitus. (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care20: 1183-1197.
85.
The Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. (2002) Third report of the national cholesterol education program (Ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel Iii) final report. Circulation 106: 3143-3421.
86.
Thom, T., Haase, N., Rosamond, W., Howard, V.J., Rumsfeld, J., Manolio, T. et al. (2006) Heart Disease and Stroke Statistics-2006 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation113: e85-151.
87.
Tirschwell, D.L., Smith, N.L., Heckbert, S.R., Lemaitre, R.N., Longstreth Jr, W.T., Psaty, B.M. (2004) Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology63: 1868-1875.
88.
Turpie, A.G. (2008) New oral anticoagulants in atrial fibrillation . Eur Heart J29: 155-165.
89.
Ukpds-Group-Investigators. (1998a) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (Ukpds 33). Uk prospective diabetes study (Ukpds) group. Lancet352: 837-853.
90.
Ukpds-Group-Investigators. (1998b) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: Ukpds 38. Uk prospective diabetes study group. Bmj317: 703-713.
91.
Vasan, R.S., Beiser, A., Seshadri, S., Larson, M.G., Kannel, W.B., D'agostino, R.B. et al. (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham heart study. Jama287: 1003-1010.
92.
Vasan, R.S., Larson, M.G., Leip, E.P., Evans, J.C., O'donnell, C.J., Kannel, W.B. et al. (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med345: 1291-1297.
93.
Vermeer, S.E., Sandee, W., Algra, A., Koudstaal, P.J., Kappelle, L.J. and Dippel, D.W. (2006) Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke . Stroke37: 1413-1417.
94.
Voko, Z., Hollander, M., Koudstaal, P.J., Hofman, A. and Breteler, M.M. (2004) How do american stroke risk functions perform in a western european population? Neuroepidemiology23: 247-253.
95.
Wattigney, W.A., Mensah, G.A. and Croft, J.B. (2003) Increasing trends in hospitalization for atrial fibrillation in the united states, 1985 through 1999: implications for primary prevention. Circulation108: 711-716.
96.
Williams, G.R. (2001) Incidence and characteristics of total stroke in the United States. BMC Neurol1: 2.
97.
Wolf, P.A. (2004) Epidemiology of Stroke. In: Mohr, J.P., Dennis, W.C., Grotta, J.C. and Wolf, P.A. (ed.) Stroke, pathophysiology, diagnosis, and management , Vol. 1. 4th edn: Elsevier Publishing: Boston, pp. 13-34.
98.
Wolf, P.A., Abbott, R.D. and Kannel, W.B. (1991) Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke22: 983-988.
99.
Wolf, P.A., D'agostino, R.B., Belanger, A.J. and Kannel, W.B. (1991) Probability of stroke: A risk profile from the framingham study. Stroke22: 312-318.
100.
Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. and Dagenais, G. (2000) Effects of an Angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med342: 145-153.
